Summary
This study is open to adults with extensive stage small cell lung cancer. The study is in
people with advanced cancer that are eligible for standard of care including chemotherapy
and anti-PD-L1 (Programmed Cell Death Ligand 1) immunotherapy.
The purpose of this study is to find out the highest dose of BI 764532 that people can
tolerate when taken together with standard of care. BI 764532 is an antibody-like
molecule that may help the immune system fight cancer. Participants get BI 764532 and
different standard treatments as infusions into a vein.
If there is benefit for the participants and if they can tolerate it, the treatment is
given for the entire duration of the study. During this time, participants visit the
study site regularly. The visits also depend on the response to the treatment. At the
study visits, the doctors check the health of the participants, take necessary laboratory
tests, and note any health problems that could have been caused by the study treatment.